| Name | Title | Contact Details |
|---|
InsightFinder provides innovative machine learning technology to unlock the value in IT operational data, from performance metrics to textual log files, finding root causes for deviations from normal behaviors and recurring patterns, as well as predicting future events and outages, involving your staff only when necessary and appropriate to do so. InsightFinder`s core technologies and patented solutions are available via online subscription or on-premise deployment. InsightFinder is the result of more than 15 years of research and development and has been evaluated and licensed by leading tech companies such as Google. In 2016, InsightFinder Inc. was launched with a highly competitive National Science Foundation Small Business Innovation Research (NSF SBIR) phase I award ($150K, also known as America`s Seed Fund). InsightFinder was then awarded two even more competitive grants; NSF SBIR Phase II award in 2017 ($750K), followed by a subsequent NSF SBIR Phase IIB award in 2018 ($500K). Over 4 million dollars funded the research behind InsightFinder`s development in research grants from the National Science Foundation, Google, IBM, and Credit Suisse.
Explore Repslys retail execution platform and discover solutions for merchandising, field sales, and promotion execution. Learn how your field team can work smarter with Repsly today!
CloudTech is a cloud-based software development and training company based in Pakistan. They provide software development and training services utilizing the latest web and mobile development frameworks.
Advanced Planning Scheduling (APS) & Management Software for production scheduling, design and control, constraints visibility, Gantt, SAP, ERP, MES.
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.